133 related articles for article (PubMed ID: 20027105)
1. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
[TBL] [Abstract][Full Text] [Related]
2. Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.
Luo WL; Crumley T; Ebel D; Atiee GJ; Royalty J; Johnson-Levonas AO; Wagner J; Lai E
J Clin Pharmacol; 2010 Nov; 50(11):1273-9. PubMed ID: 20107202
[TBL] [Abstract][Full Text] [Related]
3. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
[TBL] [Abstract][Full Text] [Related]
4. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
5. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure.
Massie BM; O'Connor CM; Metra M; Ponikowski P; Teerlink JR; Cotter G; Weatherley BD; Cleland JG; Givertz MM; Voors A; DeLucca P; Mansoor GA; Salerno CM; Bloomfield DM; Dittrich HC;
N Engl J Med; 2010 Oct; 363(15):1419-28. PubMed ID: 20925544
[TBL] [Abstract][Full Text] [Related]
6. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Cotter G; Dittrich HC; Weatherley BD; Bloomfield DM; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2008 Oct; 14(8):631-40. PubMed ID: 18926433
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous zanamivir on cardiac repolarization.
Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
9. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects.
Bloomfield DM; Krishna R; Hreniuk D; Hickey L; Ghosh K; Bergman AJ; Miller J; Gutierrez MJ; Stoltz R; Gottesdiener KM; Herman GA; Wagner JA
J Clin Pharmacol; 2009 Aug; 49(8):937-46. PubMed ID: 19602719
[TBL] [Abstract][Full Text] [Related]
10. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
11. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
12. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
13. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
14. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
Dittrich HC; Gupta DK; Hack TC; Dowling T; Callahan J; Thomson S
J Card Fail; 2007 Oct; 13(8):609-17. PubMed ID: 17923351
[TBL] [Abstract][Full Text] [Related]
15. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
Munster PN; Rubin EH; Van Belle S; Friedman E; Patterson JK; Van Dyck K; Li X; Comisar W; Chodakewitz JA; Wagner JA; Iwamoto M
Clin Cancer Res; 2009 Nov; 15(22):7077-84. PubMed ID: 19887475
[TBL] [Abstract][Full Text] [Related]
16. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of vardenafil and sildenafil on cardiac repolarization.
Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
[TBL] [Abstract][Full Text] [Related]
18. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
19. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.
Weatherley BD; Cotter G; Dittrich HC; DeLucca P; Mansoor GA; Bloomfield DM; Ponikowski P; O'Connor CM; Metra M; Massie BM;
J Card Fail; 2010 Jan; 16(1):25-35. PubMed ID: 20123315
[TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo- and moxifloxacin-controlled thorough QT study.
Green CL; Whellan DJ; Lambe L; Bellibas SE; Wijngaard P; Prats J; Krucoff MW
J Cardiovasc Pharmacol; 2013 Nov; 62(5):466-78. PubMed ID: 23921301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
